FDA eyes Amgen, Genzyme drugs for radiological/nuclear MCMs
This article was originally published in Scrip
While the bombs that were triggered by terrorists on 15 April in Boston did not contain radioactive materials, in the wake of that disaster, which demonstrated the ease at which an explosive device could be placed in a crowd unnoticed, and the ongoing threat from North Korea, the FDA is convening its first-ever advisory committee meeting to consider medical countermeasures (MCM) for use in the radiological/nuclear incident setting on 3 May.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.